GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: VX-121 | VX121
vanzacaftor is an approved drug
Compound class:
Synthetic organic
Comment: Vanzacaftor (VX-121) is a cystic fibrosis transmembrane regulator (CFTR) protein corrector for class II CFTR mutations (the most common being F508del). Its biological activity is similar to that of elexacaftor. Like elexacftor, off-target effects on K+ channels have been reported [2].
|
|
References |
1. Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M et al.. (2025)
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med, 13 (3): 256-271. [PMID:39756424] |
2. Kolski-Andreaco A, Taiclet S, Myerburg MM, Sembrat J, Bridges RJ, Straub AC, Wills ZP, Butterworth MB, Devor DC. (2024)
Potentiation of BKCa channels by cystic fibrosis transmembrane conductance regulator correctors VX-445 and VX-121. J Clin Invest, 134 (16). [PMID:38954478] |